Background: Because obesity might affect pharmacokinetic parameters, the authors evaluated the accuracy of target-controlled sufentanil infusion in morbidly obese patients using a pharmacokinetic model usually applied to a normal-weight population.
TARGET-CONTROLLED infusion (TCI) of anesthetic drugs has been investigated and successfully imple-mented in clinical practice. 1 Averaged pharmacokinetic data sets derived from population samples of normalweight patients are generally used. In obese patients, pathophysiological modifications are likely to affect drug tissue distribution and elimination. 2, 3 So, doses for obese patients, calculated on pharmacokinetic data obtained from normal-weight individuals, might induce errors and overdoses. 4 Egan et al. 4 showed that administering an appropriate lean-person dose of remifentanil to obese patients induces deleterious side effects due to the excessively high plasma remifentanil concentration. Those authors concluded that, for opioids, lean body mass (LBM) should be a better predictor for calculating the drug dose needed. But LBM use has its limits since standard formulas or nomograms tend to overestimate LBM for obese patients. In addition, most of the published guidelines are based on total body weight. 5 Gepts et al. 6 found no relationships between sufentanil pharmacokinetic parameters and age, weight, or LBM and thus do not recommend adjusting its doses to weight or LBM. However, their conclusion might not be applicable to morbidly obese patients as none were included in the studied population. Thus, the aim of this study was to evaluate the accuracy of sufentanil TCI performance in obese patients undergoing laparoscopic gastroplasty and to determine the pharmacokinetic parameters for such a population.
Materials and Methods
This study was approved by the Nice University Ethics Committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale, Nice, France). Written informed consent was obtained from 12 obese patients scheduled to undergo laparoscopic gastroplasty. Eight vertical-banded and four adjustable silicone gastricbanding gastroplasties were performed. Obese men and women aged 18 -60 yr, with body mass index (BMI) greater than 35 kg/m 2 and American Society of Anesthesiologists physical status of I or II, were eligible for enrollment. BMI was defined as: body weight (kg)/height 2 (m). Exclusion criteria were as follows: a history of alcohol and illegal drug abuse, renal or hepatic disease or gastroesophageal reflux, concurrent medication with drugs known to interact with opioids or P-450 cytochrome. Subjects whose airway anatomy on physical examination suggested that direct laryngoscopy could be difficult were also excluded. Subjects underwent a battery of laboratory tests to exclude major illness or pregnancy, including blood chemistries, liver and renal function tests, complete blood count, and urinalysis, as well as an electrocardiogram.
Anesthetic Procedure
One hour before surgery, patients received oral hydroxyzine (100 mg) as premedication. After local anesthesia (Emla ® cream; Astra, Rueil-Malmaison, France) and noninvasive monitoring, the following blood vessels were cannulated: one forearm vein for administration of intravenous fluids, one forearm vein for administration of anesthetic drugs, and a radial artery for continuous monitoring of arterial blood pressure and for blood sampling. Saline solution was infused at a rate of 100 ml/h in addition to fluid replacement as indicated by the clinical context.
Diastolic, systolic, and mean (MAP) arterial pressures, heart rate (HR), and oxygen saturation measured by pulse oximetry (SpO 2 ) were recorded every 5 min from induction to extubation. MAP and HR baseline values were means of three rest values measured at 5-min intervals before induction.
After adequate preoxygenation, total intravenous anesthesia was induced and maintained with propofol and sufentanil using a TCI system. A bolus dose of atracurium (0.6 mg/kg) was given intravenously after onset of unconsciousness to facilitate tracheal intubation. During surgery, atracurium was continuously infused at a rate of 0.4 mg · kg Ϫ1 · h Ϫ1 . Muscle relaxation was monitored with a train-of-four nerve stimulator. After intubation, the patient's lungs were ventilated with an air-oxygen mixture (50% oxygen), with maintenance of the endexpired carbon dioxide concentration at 4.5-5%. Warming blankets were used to maintain esophageal temperature at 35.5-36.5°C.
A TCI Diprifusor ® (Zeneca, London, United Kingdom) was used for propofol infusion. For induction of anesthesia and intubation, the targeted plasma propofol concentration of 6 g/ml was achieved within 2 min. During surgery, the target concentration was 3 g/ml. Propofol TCI was discontinued at wound closure. The weight used to determine the propofol infusion rate was calculated using the following formula 7 Sufentanil TCI was administered with a BD Pilot Anesthesia ® pump (Fresenius-Vial, Brezins, France) connected via a serial RS-232 interface to a personal computer running the STANPUMP software.# Unlike propofol, no weight correction was made for sufentanil. The intercompartment transfer constants and the central compartment volume of distribution (Vc) were taken from the pharmacokinetic sets of Gepts et al., 6 while the transfer constant k e0 between the central compartment and the effect site was from Scott et al. 8 The target effect-site sufentanil concentration for induction and maintenance of anesthesia was 0.4 ng/ml. We targeted the effect site for sufentanil to minimize the time to equilibrate the plasma concentration with the effect site; it took 6 min to obtain the targeted concentration. During surgery, the target concentration was adjusted to MAP and HR: Variation of both or either more than 15% above or below baseline values induced a 0.05-ng/ml increment of the target sufentanil concentration in the same direction. The predicted effect-site concentration had to reach the target before a new concentration change could be attempted. Sufentanil TCI was stopped at pneumoperitoneum exsufflation. Hypotension (MAP Ͻ 60% of baseline value) was treated with intravenous ephedrine. Atracurium was stopped 30 min before the end of surgery. Tracheal extubation was performed in the recovery room using the following criteria: spontaneous ventilation (rate Ͼ 10 breaths/min, SpO 2 Ͼ 98%, end-tidal pressure of carbon dioxide [PETCO 2 ] Ͻ 45 mmHg), opening eyes on verbal command and a train-of-four ratio greater than 0.8. Postoperative pain management included propacetamol (2 g, Prodafalgan ® ; UPSA, Rueil-Malmaison, France) administered 1 h before the end of surgery and, in the recovery room, incremental morphine doses as a function of pain assessed with a visual analog scale.
Blood Sample Processing and Sufentanil Assay
Arterial blood samples (4 ml) for measurement of plasma sufentanil concentrations were obtained immediately before the injection of sufentanil and 2, 5, 15, 30, 45, and 60 min after and then every 15 min until the end of the infusion. Additional samples were collected 5, 10, 20, 30, 45, 60, and 90 min and 2, 4, 8, 12, and 24 h after the end of the infusion. All blood samples were collected in heparinized tubes, and the plasma was separated (3,500 rpm for 10 min) and frozen (Ϫ75°C) until analysis. Plasma sufentanil concentrations were determined by radioimmunoassay, after extraction with solvent (nheptane-isoamyl alcohol, 95/5 v/v). 9, 10 The limit of quantification was 0.02 ng/ml. For a concentration range of 0.05-10 ng/ml, the interassay and intraassay coefficients of variation (CV) were less than 10% with 90% accuracy as assessed with quality-control samples prepared independently in blank human plasma and stored under the same conditions as patient samples.
Predictive Accuracy Analysis
The predicted target concentrations (effect site and plasma) and the corresponding sufentanil infusion rate were recorded every 10 s by the STANPUMP software.
The predicted concentrations were calculated by computing simulation 2 h after stopping the infusion. Data were analyzed using Excel 97 (Microsoft Corporation, Redmond, WA) and Statview 5.0 (SAS Institute Inc., Cary, NC). First, for each blood sample, the percent performance error (PE) of the predicted plasma sufentanil concentrations was calculated according to the formula: PE ϭ (Cm Ϫ Cp)/Cp ϫ 100, where Cm and Cp are, respectively, measured and predicted plasma sufentanil concentrations. PE gives an indication of the bias of the measured concentrations, and the absolute PE value is an estimation of the precision (inaccuracy). As recommended by Varvel et al., 11 intrasubject data analysis consisted of an evaluation of four indicators of predictive performance for the n subjects (Appendix): (1) median PE (MDPE): the percent MDPE reflects the bias of TCI in the ith subject; (2) median absolute PE (MDAPE): the percent MDAPE indicates the inaccuracy of TCI in the ith subject; (3) divergence characterizes performance stability over time; and (4) wobble measures the intrasubject variability of PE. MDPE, MDAPE, and divergence were calculated for samples obtained during sufentanil infusion and the 24 h after its termination.
Population Pharmacokinetic Modeling
Concentration-time data were analyzed using a nonlinear mixed-effects model, as implemented in the program NONMEM. 12 Two-and three-compartment pharmacokinetic models with zero-order input and first-order elimination were tested to fit the data. The following models were used to describe the intersubject variability of the pharmacokinetic parameters: P j ϭ P pop (1 ϩ pj ) proportional model; P j ϭ P pop ϩ pj additive model; in which P j is a kinetic parameter of the jth individual, P pop is the population mean value of the parameter, and pj is the interindividual error, distributed normally with a mean of zero and variance equal to 2 . Several error models (additive, proportional, or both) were applied to describe residual variability. A first analysis was performed to find the basic structural model that would best define the data. The model was selected on plots (measured vs. predicted concentration, weighted residuals vs. predicted concentration, weighted residuals vs. time), the value of the NONMEM objective function (goodness of fit), and the lowest estimate of the interindividual and residual variabilities. The basic model estimated the pharmacokinetic parameters without any covariates. Once it was established, the influence of each covariate (sex, age, height, body weight, and BMI) on the pharmacokinetic parameters was tested. The measured-versus-predicted concentration curve, the change of objective functions, and the change of parameter variability were recorded. A lower objective function value of at least 6.61 (chi-square distribution with one degree of freedom for P Ͻ 0.01) compared to the basic pharma-cokinetic model was required for the inclusion of a single parameter in the model. Covariates that significantly reduced the objective function were then combined in a stepwise fashion until no further reduction of the objective function was obtained (full model). An intermediate multivariate model was then established including all significant covariates. Finally, to retain only the covariates with the best abilities to predict sufentanil concentration in a final model, an objective function change of at least 10.82 (P Ͻ 0.001) was required for a single parameter during backward stepwise multiple regression analysis.
Statistical Analysis
Descriptive statistics for predictive accuracy included means, SDs, 95% confidence intervals (CIs), medians, and the 10th and 90th percentiles. Indicators predictive of performance differ significantly from zero if their 95% CIs do not include zero. Least-squares linear regression was used to evaluate relationships among BMI, weight, age, and performance parameters and to evaluate the relationship between Cp and Cm. The Wilcoxon test was used for paired data. Inaccuracy, bias, and divergence were thus compared between the whole blood-sampling period, the infusion period, and the postinfusion period. Results are expressed as mean Ϯ SD, as mean (range), or median (range). A P value less than 0.05 was considered significant.
Results
One patient was excluded because of a registration error of the doses administered by the STANPUMP software (disconnection between the computer and the The range of the applied target sufentanil concentration was 0.3-0.65 ng/ml. The mean plasma sufentanil concentration measured between incision and wound closure was 0.39 ng/ml (range, 0.18 -0.94). The mean Ϯ SD sufentanil plasma concentration measured during spontaneous ventilation was 0.13 Ϯ 0.03 ng/ml (range, 0.07-0.18 ng/ml). Target sufentanil concentrations were modified a mean four times (range, 2-10). Tables 3 and 4 show the results of the four calculated indicators (MDPE, MDAPE, divergence, and wobble) predictive of performance for the pharmacokinetic models during the whole study period, during and after sufentanil infusion. The median MDPE was negative, and the bias did not differ significantly from zero, as the 95% CI included zero. The MDAPE was 26.3% (range, 7.6 -43.6%) during infusion and 16.9% (range, 12.0 -59.5%) for the 24 h after the end of infusion. The pharmacokinetic sets used slightly overpredicted the concentrations, with a diver-gence negative value of Ϫ3.4% (95% CI, Ϫ10.2 to 3.1%) during infusion. Predicted sufentanil concentrations were significantly correlated with measured concentrations ( fig. 1 ). Concentration-versus-time curves from the patients with the best, median, or worst performances of the sufentanil pharmacokinetic model are given in figure 2 . As shown by the Cm/Cp-versus-time curves, sufentanil concentrations were not systematically overpredicted, especially during the first 240 min ( fig. 3 ). Indeed, for some patients, the model underpredicted the measured sufentanil concentrations. There was a negative correlation between bias and BMI (r 2 ϭ 0.52, P Ͻ 0.05), and sufentanil plasma concentrations being overestimated for BMI greater than 40 kg/m 2 ( fig. 4 ). No relationship was found between BMI and inaccuracy, wobble, or divergence, or between each of the four indicators predictive of performance and weight.
A two-compartment model with drug-infusion input and first-order elimination best described the measured plasma sufentanil concentrations ( fig. 5 ). With a threecompartment model, it was impossible to define all the interindividual variabilities, and the model appeared to be unstable. Thus, the two-compartment model was Table 3 6 ). The predictive accuracy analysis of our pharmacokinetic model is reported in tables 3 and 4.
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Discussion
A mean 20 -30% variation of measured concentrations above or below targeted anesthetic drug concentrations, with a maximum of 50 -60%, can be considered clinically acceptable. 13 However, variability may result from a variety of different possible sources of variability in a TCI model. Particularly, patients receiving TCI do not necessarily belong to the same population as that to develop the original pharmacokinetic model. In moderately obese patients, pharmacokinetic differences have been reported for opioids, such as remifentanil 4 or sufentanil. 14 Consequently, applying a pharmacokinetic model derived from a population of normal-weight individuals could lead to errors in obese patients. 4 However, we found that a pharmacokinetic model-driven infusion device using the sufentanil pharmacokinetic parameters described by Gepts et al. 6 performed well in morbidly obese patients and was adequate for sufentanil TCI.
Different standard definitions of overweight have been proposed. 15 Traditionally, obesity has been defined as body weight greater than 30% above IBW on standard height-weight tables. At present, it is usually defined in terms of BMI, with normal values of 23 kg/m 2 for men and 21 kg/m 2 for women. Our patients were morbidly obese (BMI Ͼ 35 kg/m 2 ). 16 The kinetics of plasma concentrations differ widely depending on whether the pump is targeting the effect site or the plasma. Because of the difficulty to rapidly change the drug effect while targeting the plasma, we targeted the sufentanil effect site. Propofol was chosen because of its good pharmacokinetic and pharmacodynamic properties for induction and maintenance of anesthesia in the obese. 7 Considering the moderately increased steady state plasma concentrations in obese patients during propofol infusion at constant rates (3, 6, and 9 mg · kg Ϫ1 · h Ϫ1 ), some authors suggested that the combination of a fixed dose and a body weight-adapted dose would be preferable. 7, 17 The target concentration and the corrected weight we used provided adequate anesthetic levels without marked hemodynamic effects. 7, 17 Recovery of consciousness is governed not only by the decrease of the propofol effect-site concentration relative to the opioid effect-site concentration, but also by the pharmacodynamic interaction between these agents. 18 In combination with propofol (3 g/ml), a sufentanil effect-site concentration of 0.4 ng/ml achieved "deep" anesthesia with more rapid recovery of consciousness than with alfentanil or fentanyl. 18 During surgery, the sufentanil concentrations we measured were similar to those necessary to reduce the isoflurane minimum alveolar concentration by at least 60% (0.2-0.5 ng/ml). 19 Sufentanil concentrations determined during anesthesia and recovery were similar to sufentanil EC 50 -EC 95 concentrations that assure adequate anesthesia and rapid return to consciousness during cardiac surgery or when sufentanil is coadministered with propofol. 18, 20, 21 In clinical practice, stopping the infusion at pneumoperitoneum exsufflation allows safe ex-tubation with sufficient residual analgesia during recovery. The times to spontaneous ventilation and tracheal extubation for our patients were similar to those observed when bolus intravenous sufentanil was coadministered with propofol TCI. 22 The plasma sufentanil concentration measured at the beginning of spontaneous ventilation was half that defined by Shafer and Varvel (0.25 ng/ml), being consistent with these events, 21 but assured sufficient residual analgesia during recovery. 23, 24 Although several sufentanil pharmacokinetic models for obese patients receiving bolus injections 14 or for normal-weight patients on TCI have been published, 6, 25 it is important to select the proper pharmacokinetic parameters because, should these parameters be strongly biased, a large PE would be expected. Brusset et al. 26 showed that blood sampling is required for a long time after sufentanil discontinuation to obtain a precise estimation of the pharmacokinetic parameters. When a low dose of a drug is given, as in TCI, plasma drug concentrations may fall below the limits of detection before the terminal phase. So, the half-life is shortened, the volume of distribution is diminished, and Cl is increased. In some patients, our period of blood sampling was inferior to 24 h. This may explained the difference that we observed in the terminal half-life and Vp with Gepts. Data concerning the use and accuracy of sufentanil administered by TCI are sparse and contradictory, varying with the population studied and the models used. Kern et al. 27 examined the performance of a pharmacokinetic model-driven infusion device using the sufentanil parameter sets derived from a pediatric population. Their model was correlated to age and weight, and the predictive accuracy of plasma sufentanil concentrations was good (MDAPE, 32%). Better results with TCI are usually obtained in children, whose pharmacokinetic variabilities might be lower because of the general lack of chronic disease and more narrow weight distribution at any given age when compared with adults. 28 Bailey et al. 20 evaluated the accuracy of sufentanil TCI using the model of Hudson 25 in adults undergoing cardiac surgery. Sufentanil was the only anesthetic agent. Plasma sufentanil concentrations revealed great bias and inaccuracy (MDPE of 116% and MDAPE of 130%) in spite of the strong correlation between measured and predicted concentrations (r 2 ϭ 0.77, P Ͻ 0.05). Very little has been published about sufentanil TCI for noncardiac surgery, and nothing has been published concerning obese patients. Schraag et al. 29 studied bias (mean PE) and precision (mean absolute PE) of sufentanil TCI after discontinuation and during recovery, also using the pharmacokinetic variable sets of Hudson. The TCI bias and inaccuracy were Ϫ17 and 20.1%, respectively. Thus, the Hudson model slightly overestimated the plasma sufentanil concentration after the infusion had been stopped.
Gepts et al. 6 defined another pharmacokinetic parameter set based on their dose-range study. The Gepts Our results confirmed that the Gepts model can also be applied to obese patients. The population pharmacokinetic model with our data gave results similar to those obtained with the Gepts model in terms of pharmacokinetic parameters and accuracy. However, our model's bias was negative, but it was not significantly different from zero. Therefore, based on our model, it is not possible to know if sufentanil concentrations will be under estimated or overestimated. Nevertheless, a linear relationship was found between bias and BMI during sufentanil infusion. For a BMI greater than 40 kg/m 2 , Cm was lower than Cp. That finding might be explained by a higher Vd and/or increased clearance as a function of excess body weight. A pharmacokinetic analysis using a population approach was performed to determine whether the estimated parameters were different in our patients and could explain this lower Cm. The twocompartment model was used to investigate whether certain covariates could improve the fit and decrease the interindividual variability. However, none of the demographic parameters tested (particularly weight and BMI) were able to significantly lower the objective function. Clearance tended to increase with BMI, whereas the Vc was independent. Wada et al. 31 also observed this relationship between clearance and obesity (Cl: lean ϭ 0.21 l/min, ϩ50% overweight ϭ 0.26 l/min, ϩ100% overweight ϭ 0.29 l/min). This enhanced Cl may be due to increased hepatic blood flow. Because the hepatic extraction ratio of sufentanil is around 0.6 -0.8, its Cl relies mainly on hepatic blood flow. These measured results suggest that the concentration predicted by the Gepts model could be overestimated as a consequence of more rapid Cl in obese patients.
In conclusion, the accuracy of the pharmacokinetic parameters described by Gepts et al. 6 for sufentanil TCI is sufficient for clinical application in obese patients in combination with propofol. As of 40 kg/m 2 , the plasma sufentanil concentration overestimation rises with the increasing BMI.
